Linvoseltamab

Phase 1/2Recruiting

1 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Relapsed/Refractory Systemic Light Chain Amyloidosis

Conditions

Relapsed/Refractory Systemic Light Chain Amyloidosis

Trial Timeline

Aug 7, 2024 → Feb 20, 2035

NCT ID

NCT06292780

About Linvoseltamab

Linvoseltamab is a phase 1/2 stage product being developed by Regeneron Pharmaceuticals for Relapsed/Refractory Systemic Light Chain Amyloidosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06292780. Target conditions include Relapsed/Refractory Systemic Light Chain Amyloidosis.

What happened to similar drugs?

0 of 10 similar drugs in Relapsed/Refractory Systemic Light Chain Amyloidosis were approved

Approved (0) Terminated (1) Active (9)

🔄Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3

🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3

🔄Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclaxAbbViePhase 3

❌Blinatumomab + Standard of Care ChemotherapyAmgenPhase 3

🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3

🔄Axicabtagene Ciloleucel + Cyclophosphamide + Fludarabine + Lenalidomide + Rituximab + Doxorubicin + Vincristine + Prednisone + BendamustineGilead SciencesPhase 3

🔄Odronextamab + Lenalidomide + RituximabRegeneron PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07181941	Phase 1/2	Recruiting	Apr 1, 2026	Jun 30, 2028	Recurrent Multiple Myeloma
NCT06140524	Phase 2	Recruiting	Sep 16, 2024	May 18, 2032	Monoclonal Gammopathy of Undetermined Significance (MGUS)
NCT06376526	Phase 2	Recruiting	Aug 21, 2024	Aug 31, 2029	Multiple Myeloma
NCT06292780	Phase 1/2	Recruiting	Aug 7, 2024	Feb 20, 2035	Relapsed/Refractory Systemic Light Chain Amyloidosis
NCT05955508	Phase 2	Active	Jan 30, 2024	Jan 25, 2033	Smoldering Multiple Myeloma (SMM)
NCT05828511	Phase 1/2	Recruiting	Dec 19, 2023	Nov 2, 2035	Multiple Myeloma
NCT03761108	Phase 1/2	Recruiting	Jan 23, 2019	Jun 16, 2033	Multiple Myeloma

Competing Products

20 competing products in Relapsed/Refractory Systemic Light Chain Amyloidosis

See all competitors

Product	Company	Stage	Hype Score
mRNA-2752 + Durvalumab	AstraZeneca	Phase 1	29
mRNA-2416	Moderna	Phase 2	0
agenT-797	MiNK Therapeutics	Phase 1	19
Valemetostat Tosylate	Daiichi Sankyo	Phase 2	39
Eribulin mesylate	Eisai	Phase 2	35
Tirabrutinib + Rituximab + Temozolomide	Ono Pharmaceutical	Phase 3	47
Epcoritamab + Epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone + Venetoclax + Epcoritamab + Lenalidomide + Epcoritamab + Pirtobrutinib + Epcoritamab	Eli Lilly	Phase 1/2	36
ISB 1342	Glenmark Pharmaceuticals	Phase 1	29
SHR2554; Chidamide analog tablets + SHR2554 analog tablets; Chidamide	Jiangsu Hengrui Medicine	Phase 3	47
Linperlisib ； Rituximab	Jiangsu Hengrui Medicine	Phase 1/2	39
Epcoritamab + Epcoritamab, lenalidomide and rituximab	AbbVie	Phase 2	42
Etentamig	AbbVie	Phase 1	33
Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclax	AbbVie	Phase 3	40
Etentamig + Dexamethasone + Lenalidomide + Pomalidomide + Daratumumab	AbbVie	Phase 1	33
[14C]ABT-199 (GDC-0199)	AbbVie	Phase 1	21
ABT-199 + bortezomib + dexamethasone	AbbVie	Phase 1	29
Venetoclax + Dexamethasone	AbbVie	Phase 1/2	32
ABBV-453 + Dexamethasone + Daratumumab + Lenalidomide	AbbVie	Phase 1	33
AZD4573	AstraZeneca	Phase 2	35
Moxetumomab Pasudotox	AstraZeneca	Pre-clinical	26